SiBone (SIBN) Expected to Release Quarterly Earnings on Monday

SiBone (NASDAQ:SIBN) is anticipated to release its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $55.27 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. On average, analysts expect SiBone to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

SiBone Price Performance

SiBone stock opened at $16.62 on Monday. The stock has a 50-day moving average price of $15.92 and a two-hundred day moving average price of $15.20. SiBone has a 12 month low of $11.48 and a 12 month high of $21.89. The company has a market capitalization of $737.10 million, a PE ratio of -42.62 and a beta of 0.67. The company has a current ratio of 9.99, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20.

Insider Transactions at SiBone

In other SiBone news, Director Jeffrey W. Dunn sold 3,575 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $15.25, for a total value of $54,518.75. Following the sale, the director owned 16,057 shares in the company, valued at approximately $244,869.25. The trade was a 18.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Anshul Maheshwari sold 3,317 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $16.77, for a total value of $55,626.09. Following the completion of the sale, the chief financial officer directly owned 256,560 shares of the company’s stock, valued at approximately $4,302,511.20. The trade was a 1.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 36,326 shares of company stock worth $545,661. 4.00% of the stock is currently owned by insiders.

Institutional Trading of SiBone

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after purchasing an additional 1,053 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of SiBone in the 1st quarter worth approximately $225,000. Goldman Sachs Group Inc. boosted its stake in shares of SiBone by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after purchasing an additional 83,919 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of SiBone in the 1st quarter valued at $1,818,000. Finally, Legal & General Group Plc increased its position in shares of SiBone by 16.1% during the second quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock worth $798,000 after buying an additional 5,888 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Ratings Changes

SIBN has been the subject of several recent research reports. Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Truist Financial lifted their target price on shares of SiBone from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, TD Cowen decreased their price target on shares of SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.50.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.